U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 77 results

Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Olodaterol is a beta2-adrenoceptor agonist discovered by Boehringer Ingelheim and approved for the treatment of Chronic Obstructive Pulmonary Disease. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors af...
Status:
US Approved Rx (2017)
First approved in 2013

Class (Stereo):
CHEMICAL (ABSOLUTE)



Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmona...
Status:
US Approved Rx (2017)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Umeclidinium (used as a bromide salt) is a long-acting, antimuscarinic antagonist, often referred to as an anticholinergic, developed for the treatment of chronic obstructive pulmonary disease (COPD) (alone and in combination with Vilanterol - long-a...
Status:
US Approved Rx (2012)
First approved in 2012

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. It has a much higher propensity to bind t...
Status:
US Approved Rx (2020)
First approved in 2011

Class (Stereo):
CHEMICAL (ACHIRAL)



Roflumilast is a specific phosphodiesterase type (4PDE4) inhibitor indicated for use as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Status:
US Approved Rx (2014)
First approved in 2007

Class (Stereo):
CHEMICAL (ABSOLUTE)



Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Fluticasone furoate is a anti-allergic agents that is FDA approved for the treatment of symptoms of seasonal and perennial allergic rhinitis, ast...
Status:
US Approved Rx (2007)
First approved in 2006

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had...
Status:
US Approved Rx (2023)
First approved in 2004

Class (Stereo):
CHEMICAL (ACHIRAL)



Tiotropium is a long–acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of ...
Status:
US Approved Rx (2022)
First approved in 2001

Class (Stereo):
CHEMICAL (RACEMIC)



Formoterol is a long-acting selective beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist acti...
Status:
US Approved Rx (1998)
First approved in 1998

Class (Stereo):
CHEMICAL (ABSOLUTE)



Montelukast (SINGULAIR®) is a selective and orally active leukotriene D4 (LTD4) receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. It is indicated for the prophylaxis and chronic treatment of asthma, for prevention of exerci...